BioCentury
ARTICLE | Company News

Aslan, Nanyang Technological University deal

October 17, 2016 7:00 AM UTC

Aslan partnered with the university to research and develop Modybodies, which are stabilized heavy chain mAb fragments, against three targets of Aslan’s choice. Aslan said the fragments are designed for higher tissue penetration due to their small size. Aslan has an exclusive option to gain worldwide rights to develop and commercialize the programs for pre-negotiated, undisclosed terms. The company expects the first clinical study of a Modybody to begin in 2018. The partners did not respond to inquiries. ...